Gaurav Sahay is an Assistant Professor in the Department of Pharmaceutical Sciences, College of Pharmacy at Oregon State University. Dr. Sahay completed his postdoctoral research with Prof. Robert Langer and Prof. Daniel Anderson at MIT and received his Ph.D. from the University of Nebraska Medical Center under the mentorship of Prof. Alexander Kabanov. Dr. Sahay’s lab is developing novel nanotechnology-based platforms for effective delivery of messenger RNA therapeutics for treatment of rare disorders including cystic fibrosis, retinal degeneration and lysosomal storage disorders. He has done pioneering work to dissect the intracellular transport essential for nucleic acid delivery to the cytosol and developed methods to overcome endosomal barriers. He has more than 43 peer-reviewed publications in top tier journals including Nature, Nature Biotechnology, Nature Nanotechnology, Journal of Controlled Release, Nano Letters etc. He is the winner of a 2013 American Association of Pharmaceutical Scientists (AAPS) Postdoctoral Fellow Award, the 2015 Controlled Release Society (CRS) T. Nagai Award, a 2016 American Association of Colleges of Pharmacy (AACP) New Investigator Award, and a 2019 Oregon Health & Sciences University (OHSU) Distinguished Faculty Senate Award for Collaboration. He serves as the Principal Investigator on awards funded through the National Institutes of Health, Medical Research Foundation of Oregon, Moderna Therapeutics, Cystic Fibrosis Foundation, and OSU and has served as a consultant and scientific advisory board member to several biotech and venture capital firms. He was the Chair of the 2018 NanoMedicine and Drug Delivery Symposium (NanoDDS, Portland, OR) and is the current Chair of CRS Gene Delivery and Gene Editing Focus Group.